A Phase 3 interventional study of Glycopyrronium/Formoterol Fumarate and umeclidinium/vilanterol in Chronic Obstructive Pulmonary Disease COPD, sponsored by AstraZeneca. Completed at 107 sites in 7 countries. Open to participants aged 40 Years to 95 Years. Per ClinicalTrials.gov, last updated 2019-05-22.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 10th largest by enrollment, is one of 4 that started in 2017, is one of 33 in phase 3, and was the 59th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,119 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 30th largest by enrollment of the 194 interventional ones that give a count, is one of 14 that started in 2017, is one of 76 in phase 3, and was the 205th registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
This is a phase IIIb randomised, double-blind, double-dummy, multicentre, parallel group, 24 week study to assess the efficacy and safety of Glycopyrronium/Formoterol Fumarate (GFF) fixed-dose combination 7.2/4.8 μg 2 inhalations twice daily compared to Umeclidinium/Vilanterol (UV) 62.5/25 μg fixed-dose combination 1 inhalation once daily in Patients with moderate to very severe COPD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
glycopyrronium/formoterol fumarate 7.2/4.8 μg per actuation, twice daily
Drug: Glycopyrronium/Formoterol Fumarate
umeclidinium/vilanterol 62.5/ 25μg per inhalation, once daily
Drug: umeclidinium/vilanterol
Drug pages: Glycopyrrolate · Formoterol
Metered dose inhaler (MDI), contains glycopyrronium/formoterol fumarate fixed-dose combination 7.2/4.8 μg per actuation
Drug pages: GSK573719 · Vilanterol
Dry powder inhaler (DPI), Each metered dose contains umeclidinium/vilanterol 62.5/ 25μg fixed-dose combination per inhalation
Mean Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) Over 24 Weeks
To assess the effects of GFF relative to UV on lung function as measured by change from baseline in morning pre-dose trough FEV1 is defined as the average of the -60 and -30 minute pre-dose values at each visit minus baseline using spirometry. Baseline is defined as the mean of the non-missing -60 and -30 minute values obtained prior to dosing at randomization (Day 1). BR a/s = bronchodilator responsiveness to albuterol/salbutamol.
Time frame: From Baseline (Day 1) up to 24 weeks
Mean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks in PP Analysis Set Population
To assess the effects of GFF relative to UV on lung function in PP analysis set population as measured by peak change from baseline in FEV1 is defined as the maximum of the FEV1 assessments within the 2 hours post-dosing time windows at each visit minus baseline using spirometry. Baseline is defined as the mean of the non-missing -60 and -30 minute values obtained prior to dosing at randomization (Day 1).
Time frame: From Baseline (Day 1) up to 24 weeks
Mean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks in FAS Population
To assess the effects of GFF relative to UV on lung function in FAS population as measured by peak change from baseline in FEV1 is defined as the maximum of the FEV1 assessments within the 2 hours post-dosing time windows at each visit minus baseline using spirometry. Baseline is defined as the mean of the non-missing -60 and -30 minute values obtained prior to dosing at randomization (Day 1).
Time frame: From Baseline (Day 1) up to 24 weeks
Percentage of Participants With Increase of FEV1 of >=100 mL From Baseline at 5 Minutes Post-dosing on Day 1
The percentage of participants with an increase in FEV1 of \>=100 mL from baseline at 5 minutes post-dosing on Day 1 was determined to assess the early onset of action. Baseline is defined as the average of available evaluable -60 and -30 minute pre-dose assessments conducted at randomization (Day 1). Only data assigned to the 5 minute window was used to determine response. Participants with missing data were considered non-responders for the analysis.
Time frame: 5 minutes post-dose on Day 1
Mean Peak Change From Baseline in Inspiratory Capacity (IC) Within 2 Hours Post-dosing Over 24 Weeks
Peak change from baseline in IC is defined as the maximum of the IC assessments within the 2 hours post-dosing time windows at each visit minus baseline. Baseline is defined as the average of available evaluable -60 and -30 minute pre-dose assessments conducted at randomization (Day 1).
Time frame: From Baseline (Day 1) up to 24 weeks
Mean Transition Dyspnea Index (TDI) Focal Score Over 24 Weeks
The baseline dyspnea index (BDI) and TDI consist of 3 individual components: functional impairment, magnitude of task, and magnitude of effort. For the BDI, each of these 3 components were rated in 5 grades from 0 (very severe) to 4 (no impairment), and were summed to form a baseline total score from 0 to 12. For the TDI, changes in dyspnea were rated for each component by 7 grades from -3 (major deterioration) to +3 (major improvement), and were added to form a TDI focal score from -9 to +9. Baseline is defined as the latest BDI assessment within 7 days before or at randomization (Day 1).
Time frame: From Baseline (Day -7 or 1) up to 24 weeks
Mean Change From Baseline in Early Morning Symptoms of COPD Instrument (EMSCI) Over 24 Weeks
Change from baseline in the 6-item EMSCI Symptom Severity Score was derived by averaging the responses from a participant on the 6 item-level symptom scores (scored on a 4-point scale from 1 to 4, whereas 1= mild and 4= very severe). The EMSCI collected data about the frequency and severity of early morning symptoms and the impact of COPD symptoms on early morning activity in participants with COPD. Participants completed a daily electronic patient-reported outcome (ePRO) questionnaire for their COPD symptoms. Baseline is defined as the average of the non-missing values from the ePRO data collected in the last 7 days before the randomization (Day 1). TI = Time interval.
Time frame: From Baseline (Day -7) up to 24 weeks
Mean Change From Baseline in Night-Time Symptoms of COPD Instrument (NiSCI) Over 24 Weeks
Change from baseline in the 6-item NiSCI Symptom Severity Score was derived by averaging the responses from a participant on the 6 item-level symptom scores (scored on a 4-point scale from 1 to 4, whereas 1= mild and 4= very severe). The NiSCI collected data about the frequency and severity of night-time symptoms and the impact of COPD symptoms on night-time awakenings in participants with COPD. Participants completed a daily ePRO questionnaire for their COPD symptoms. Baseline is defined as the average of the non-missing values from the ePRO data collected in the last 7 days before the randomization (Day 1).
Time frame: From Baseline (Day -7) up to 24 weeks
Mean Change From Baseline in Daily Rescue (Albuterol/Salbutamol MDI) Use Over 24 Weeks
The number of inhalations of rescue albuterol/salbutamol MDI was recorded in the participant ePRO in the morning and evening. Baseline is defined as the average of the non-missing values from the ePRO data collected in the last 7 days before the randomization (Day 1). a/s = albuterol/salbutamol.
Time frame: From Baseline (Day -7) up to 24 weeks
Mean Change From Baseline in COPD Assessment Test (CAT) Score Over 24 Weeks
The CAT is used to quantify the impact of COPD symptoms on health status. The CAT has a scoring range of 0-40, and it is calculated as the sum of the responses given for each of the 8 items (scored on a 6-point scale from 0 to 5), with higher scores indicating a higher impact of COPD symptoms on health status. If the response to 1 of the 8 items is missing, the missing item was considered equal to the average of the 7 non-missing items for that participant. If more than 1 item is missing the score was considered missing. Baseline is defined as the latest assessment within 7 days before or at randomization (Day 1).
Time frame: From Baseline (Day -7 or 1) up to 24 weeks
This study was conducted in 110 centers in 7 countries (Russia, Bulgaria, Ukraine, United States of America, Canada, Hungary and France) between 25 May 2017 and 04 May 2018. Participants with moderate to very severe chronic obstructive pulmonary disease (COPD) were recruited in this study.
| Milestone | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| Started | 559 | 560 |
| Received treatment | 557 | 560 |
| Safety analysis set | 552 | 552 |
| Full analysis set (fas) | 552 | 552 |
| Per protocol (pp) analysis set | 506 | 510 |
| Completed | 497 | 517 |
| Not completed | 62 | 43 |
| Withdrew: Adverse event | 6 | 5 |
| Withdrew: Death | 3 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Study-specific withdrawal criteria | 22 | 14 |
| Withdrew: Withdrawal by subject | 17 | 2 |
| Withdrew: Did not receive treatment | 2 | 0 |
| Withdrew: Incorrect randomization | 4 | 3 |
| Withdrew: Other | 8 | 15 |
To assess the effects of GFF relative to UV on lung function as measured by change from baseline in morning pre-dose trough FEV1 is defined as the average of the -60 and -30 minute pre-dose values at each visit minus baseline using spirometry. Baseline is defined as the mean of the non-missing -60 and -30 minute values obtained prior to dosing at randomization (Day 1). BR a/s = bronchodilator responsiveness to albuterol/salbutamol.
| milliliter (mL) | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| Mean Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) Over 24 Weeks | 82.4 ± 11.2 | 169.6 ± 11.2 |
To assess the effects of GFF relative to UV on lung function in PP analysis set population as measured by peak change from baseline in FEV1 is defined as the maximum of the FEV1 assessments within the 2 hours post-dosing time windows at each visit minus baseline using spirometry. Baseline is defined as the mean of the non-missing -60 and -30 minute values obtained prior to dosing at randomization (Day 1).
| mL | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| Mean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks in PP Analysis Set Population | 293.5 ± 10.2 | 296.9 ± 10.3 |
The percentage of participants with an increase in FEV1 of \>=100 mL from baseline at 5 minutes post-dosing on Day 1 was determined to assess the early onset of action. Baseline is defined as the average of available evaluable -60 and -30 minute pre-dose assessments conducted at randomization (Day 1). Only data assigned to the 5 minute window was used to determine response. Participants with missing data were considered non-responders for the analysis.
| Percentage of participants | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| Percentage of Participants With Increase of FEV1 of >=100 mL From Baseline at 5 Minutes Post-dosing on Day 1 | 60.1 | 40.8 |
Peak change from baseline in IC is defined as the maximum of the IC assessments within the 2 hours post-dosing time windows at each visit minus baseline. Baseline is defined as the average of available evaluable -60 and -30 minute pre-dose assessments conducted at randomization (Day 1).
| mL | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| Mean Peak Change From Baseline in Inspiratory Capacity (IC) Within 2 Hours Post-dosing Over 24 Weeks | 363.1 ± 15.5 | 378.3 ± 15.6 |
The baseline dyspnea index (BDI) and TDI consist of 3 individual components: functional impairment, magnitude of task, and magnitude of effort. For the BDI, each of these 3 components were rated in 5 grades from 0 (very severe) to 4 (no impairment), and were summed to form a baseline total score from 0 to 12. For the TDI, changes in dyspnea were rated for each component by 7 grades from -3 (major deterioration) to +3 (major improvement), and were added to form a TDI focal score from -9 to +9. Baseline is defined as the latest BDI assessment within 7 days before or at randomization (Day 1).
| Units on a scale | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| Mean Transition Dyspnea Index (TDI) Focal Score Over 24 Weeks | 1.23 ± 0.10 | 1.60 ± 0.10 |
Change from baseline in the 6-item EMSCI Symptom Severity Score was derived by averaging the responses from a participant on the 6 item-level symptom scores (scored on a 4-point scale from 1 to 4, whereas 1= mild and 4= very severe). The EMSCI collected data about the frequency and severity of early morning symptoms and the impact of COPD symptoms on early morning activity in participants with COPD. Participants completed a daily electronic patient-reported outcome (ePRO) questionnaire for their COPD symptoms. Baseline is defined as the average of the non-missing values from the ePRO data collected in the last 7 days before the randomization (Day 1). TI = Time interval.
| Units on a scale | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| Mean Change From Baseline in Early Morning Symptoms of COPD Instrument (EMSCI) Over 24 Weeks | -0.142 ± 0.018 | -0.176 ± 0.018 |
Change from baseline in the 6-item NiSCI Symptom Severity Score was derived by averaging the responses from a participant on the 6 item-level symptom scores (scored on a 4-point scale from 1 to 4, whereas 1= mild and 4= very severe). The NiSCI collected data about the frequency and severity of night-time symptoms and the impact of COPD symptoms on night-time awakenings in participants with COPD. Participants completed a daily ePRO questionnaire for their COPD symptoms. Baseline is defined as the average of the non-missing values from the ePRO data collected in the last 7 days before the randomization (Day 1).
| Units on a scale | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| Mean Change From Baseline in Night-Time Symptoms of COPD Instrument (NiSCI) Over 24 Weeks | -0.165 ± 0.019 | -0.207 ± 0.019 |
The number of inhalations of rescue albuterol/salbutamol MDI was recorded in the participant ePRO in the morning and evening. Baseline is defined as the average of the non-missing values from the ePRO data collected in the last 7 days before the randomization (Day 1). a/s = albuterol/salbutamol.
| puffs/day | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| Mean Change From Baseline in Daily Rescue (Albuterol/Salbutamol MDI) Use Over 24 Weeks | -1.70 ± 0.16 | -2.35 ± 0.16 |
The CAT is used to quantify the impact of COPD symptoms on health status. The CAT has a scoring range of 0-40, and it is calculated as the sum of the responses given for each of the 8 items (scored on a 6-point scale from 0 to 5), with higher scores indicating a higher impact of COPD symptoms on health status. If the response to 1 of the 8 items is missing, the missing item was considered equal to the average of the 7 non-missing items for that participant. If more than 1 item is missing the score was considered missing. Baseline is defined as the latest assessment within 7 days before or at randomization (Day 1).
| Units on a scale | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| Mean Change From Baseline in COPD Assessment Test (CAT) Score Over 24 Weeks | -2.97 ± 0.21 | -3.56 ± 0.22 |
To assess the effects of GFF relative to UV on lung function in FAS population as measured by peak change from baseline in FEV1 is defined as the maximum of the FEV1 assessments within the 2 hours post-dosing time windows at each visit minus baseline using spirometry. Baseline is defined as the mean of the non-missing -60 and -30 minute values obtained prior to dosing at randomization (Day 1).
| mL | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| Mean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks in FAS Population | 299.1 ± 9.9 | 300.8 ± 9.9 |
Collected over From Baseline (Day 1) up to 14 days after last IP dose, approximately 26 weeks.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Glycopyrronium/Formoterol Fumarate | 3/552 (0.5%) | 32/552 (5.8%) | 129/552 (23.4%) |
| Umeclidinium/Vilanterol | 3/552 (0.5%) | 40/552 (7.2%) | 153/552 (27.7%) |
| Event | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 16/552 | 10/552 |
| PneumoniaInfections and infestations | 3/552 | 3/552 |
| Angina unstableCardiac disorders | 1/552 | 2/552 |
| Cardiac failure acuteCardiac disorders | 0/552 | 2/552 |
| GastroenteritisInfections and infestations | 1/552 | 2/552 |
| Pneumonia bacterialInfections and infestations | 1/552 | 2/552 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/552 | 2/552 |
| Diabetic footSkin and subcutaneous tissue disorders | 0/552 | 2/552 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/552 | 0/552 |
| Acute myocardial infarctionCardiac disorders | 1/552 | 1/552 |
| Event | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| HeadacheNervous system disorders | 34/552 | 41/552 |
| NasopharyngitisInfections and infestations | 30/552 | 36/552 |
| Viral upper respiratory tract infectionInfections and infestations | 17/552 | 26/552 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 20/552 | 20/552 |
| DiarrhoeaGastrointestinal disorders | 7/552 | 13/552 |
| HypertensionVascular disorders | 13/552 | 7/552 |
| Back painMusculoskeletal and connective tissue disorders | 12/552 | 9/552 |
| Upper respiratory tract infectionInfections and infestations | 10/552 | 10/552 |
| Abdominal painGastrointestinal disorders | 4/552 | 7/552 |
| ConstipationGastrointestinal disorders | 1/552 | 7/552 |
The FAS included all randomized participants who received at least 1 inhalation of investigational product (IP) from the GFF or UV inhaler (active or placebo).
| Age, Continuous(Years) | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol | Total |
|---|---|---|---|
| Mean | 64.3 ± 8.0 | 63.8 ± 8.1 | 64.1 ± 8.0 |
| Age, Customized(Participants) | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol | Total |
|---|---|---|---|
| <65 years | 273 | 292 | 565 |
| 65 - 74 years | 223 | 214 | 437 |
| 75 - 84 years | 53 | 43 | 96 |
| >=85 years | 3 | 3 | 6 |
| Sex: Female, Male(Participants) | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol | Total |
|---|---|---|---|
| Female | 142 | 160 | 302 |
| Male | 410 | 392 | 802 |
| Race/Ethnicity, Customized(Participants) | Glycopyrronium/Formoterol Fumarate | Umeclidinium/Vilanterol | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 13 | 10 | 23 |
| White | 538 | 542 | 1080 |
| More than one race | 0 | 0 | 0 |
| Other | 1 | 0 | 1 |
Showing the first 100 of 107 sites across 7 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from May 2017 to primary completion in May 2018, 11 months.
Results were first posted in May 2019, 1 year after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 11 months is below that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Glycopyrrolate · Formoterol
Pulmonary Disease, Chronic Obstructive →